Airway CD4+ T cells carry a distinct inflammatory program in beryllium hypersensitivity
Single-cell RNA sequencing is beginning to expose the cellular wiring behind occupational lung disease in a way bulk assays cannot. In chronic beryllium disease, the central pathology is not simply exposure-related irritation; it is the persistence and expansion of antigen-experienced CD4+ T cells in the airways, where they continue to fuel pulmonary inflammation and functional decline. This preprint used sorted viable bronchoalveolar lavage cells from beryllium-exposed patients and compared them with publicly available single-cell datasets from healthy controls, aiming to define the transcriptional features of the airway immune compartment at single-cell resolution.
The dataset was small, with bronchoalveolar lavage material from two exposed patients and comparison against 10 healthy controls, but the signal that emerged was biologically coherent. Eleven CD3-associated clusters were identified, spanning T cells, natural killer cells, and regulatory T cells. Within the CD4+ compartment, the exposed samples showed higher expression of genes tied to activation, immune regulation, and cellular persistence, including IFNG, TNF, TNFAIP3, and CD74. Those genes fit the expected biology of a lung that has not escaped immune recognition: interferon signaling, TNF-driven activation, and pathways that keep T cells in an inflamed tissue niche rather than allowing them to recede.
A single sentence captures the core finding: the airway CD4+ T cells were transcriptionally primed for chronic inflammation.
IFNG, TNF, and CD74 point to sustained airway immune activation
The gene pattern matters because it tracks with the mechanisms already suspected in metal-induced hypersensitivity. IFNG and TNF are not passive markers; they are effector cytokines that amplify antigen presentation, recruit additional inflammatory cells, and help sustain granulomatous or granuloma-like immune activity in the lung. TNFAIP3 encodes a negative regulator of NF-kappa B signaling, and its increased expression can be read as a brake being pressed in the middle of active inflammation, not as proof that inflammation has stopped. CD74, a molecule involved in antigen presentation, points toward ongoing immune surveillance and continued interaction between T cells and antigen-presenting pathways in the airway milieu.
The more provocative aspect of the transcriptomic signature is persistence. In diseases like chronic beryllium disease, airway T cells may remain positioned at the site of antigen exposure long after the initial occupational exposure has ended. That persistent tissue residence can help explain why pulmonary inflammation becomes self-sustaining and why lung function may remain impaired even when exposure is removed. Single-cell profiling is especially useful here because it distinguishes a few highly activated cellular subsets from the broader cellular background that can obscure the relevant biology in bulk sequencing.
Metabolic suppression accompanied immune activation in the exposed samples
Gene Ontology enrichment added another layer to the picture. Pathways associated with cellular activation, immune responses, and immune effector functions were upregulated in the beryllium-exposed samples, while metabolic pathways were downregulated relative to healthy controls. In practical biological terms, activated T cells often shift away from homeostatic metabolism and toward programs that support rapid effector activity and tissue survival. A drop in metabolic signatures can therefore reflect a cell population that is specialized for inflammatory endurance rather than routine immune surveillance.
This pattern fits an airway compartment locked into chronic stimulation. When T cells occupy inflamed lung tissue over time, they often reshape both their cytokine profile and their energy handling to survive in a stressed microenvironment. The resulting state is not a quiet autoimmune echo; it is an active, tissue-adapted immune program. In that context, the upregulation of immune effector pathways and the suppression of metabolic pathways look less like unrelated omics noise and more like two sides of the same pathogenic coin.
The study also identified IFI27 and FABP4 as distinct transcriptional signatures in CD4+ T cells from beryllium-exposed patients. Both genes are intriguing for biomarker development, though in different ways. IFI27 has associations with interferon-responsive states, which makes it a plausible marker of inflammatory signaling intensity. FABP4 suggests alterations in lipid handling and cellular metabolism, reinforcing the idea that airway T cells in this disease are metabolically rewired as they persist in inflamed tissue.
Biomarker and therapeutic hypotheses remain preliminary but biologically grounded
The study’s chief value lies in hypothesis generation. It points to a narrow set of candidate pathways that may help distinguish beryllium-induced hypersensitivity from non-specific airway inflammation and may eventually support earlier disease detection or patient stratification. A biomarker that reflects the activation state of airway CD4+ T cells would be especially useful in a disease where the pathological process is driven by immune persistence rather than by a fleeting exposure response.
Therapeutically, the transcriptional findings reinforce a broader strategy that has long guided pulmonary immunology: interrupt the circuits that allow pathogenic T cells to remain activated in the lung. If those cells can be redirected, silenced, or prevented from persisting in the airway niche, the inflammatory cascade downstream of exposure may weaken. The current data do not identify a treatment, and they do not establish clinical utility for any single marker, but they do narrow the biological search space in a disease that has been difficult to read at the cellular level.
A second sentence deserves its own space: two patients are not enough to define a clinical biomarker.
Small sample size limits clinical certainty
The limitations are substantial and should stay in view. The exposed cohort contained only two patients, and the control data came from publicly available healthy samples rather than a matched prospective comparator group. Cross-dataset comparisons in single-cell studies can introduce technical and biological variability, especially when the source material, processing pipeline, or underlying demographics are not harmonized. The preprint also reflects a snapshot of bronchoalveolar lavage cells rather than a longitudinal view of how airway T-cell programs evolve with exposure, symptom burden, or treatment.
Even so, the study delivers a useful first map of airway-associated CD4+ T cells in metal-induced hypersensitivity. It shows that the inflammatory signature is not vague or diffuse; it is anchored in recognizable immune effectors, antigen-presentation machinery, and metabolic reprogramming. Future work will need larger patient cohorts, matched controls, and clinical correlation with pulmonary function and disease severity before any of these candidate genes can be considered as more than experimental leads.